
    
      This is an open-label, expanded access study of KTE-X19 for the treatment of individuals with
      r/r B-cell malignancies. The study will consist of 2 cohorts as indicated below:

      Cohort 1 will enroll individuals prior to commercial availability of KTE-X19 for the proposed
      indication.

      Cohort 2 will enroll individuals after KTE-X19 becomes commercially available in cases when
      KTE-X19 does not meet commercial release specification(s).
    
  